MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

about

MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions.

P2860

Q49979233-C9A9AD97-8448-46A6-9038-D46D2942CF32 Q55370601-8F4B76CA-3DE1-4A51-B94E-94508D479EB7

P2860

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

Item

http://www.wikidata.org/entity/Q47161911

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

@en

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

@nl

type

Item

label

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

@en

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

@nl

prefLabel

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

@en

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

@nl

P1476

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

@en

P2093

Alexander S G Micko

http://www.w3.org/2001/XMLSchema#string

Christine Marosi

http://www.w3.org/2001/XMLSchema#string

Engelbert Knosp

http://www.w3.org/2001/XMLSchema#string

Romana Höftberger

http://www.w3.org/2001/XMLSchema#string

Stefan Wolfsberger

http://www.w3.org/2001/XMLSchema#string

P2860

hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular switch

Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

Genomic and molecular profiling predicts response to temozolomide in melanoma.

A structural and functional acromegaly classification

Endoplasmic reticulum protein 29 (ERp29) confers radioresistance through the DNA repair gene, O(6)-methylguanine DNA-methyltransferase, in breast cancer cells

P2888

s11102-017-0829-3

P304

643-653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11102-017-0829-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Greisa Vila

Adelheid Wöhrer

P577

2017-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28900805

http://www.w3.org/2001/XMLSchema#string

P932

5655586

http://www.w3.org/2001/XMLSchema#string

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

about

P2860

P2860

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932